OR in the News

Turan A, Fang J, Esa WAS, Hamadnalla H, Leung S, Pu X, Raza S, Chelnick D, Mounir Soliman L, Seif J, Ruetzler K, Sessler DI: Naloxegol and postoperative urinary retention: A randomized trial. J Clin Med 2022; 11: 454

October 26, 2022

Abstract:
Background: Naloxegol antagonizes peripheral opioid-related side effects without prevent- ing opioid-related analgesia. However, the effect of naloxegol on opioid-induced bladder dysfunction remains unknown. Hypothesis: patients given naloxegol have lower residual bladder urine volume than those given placebo. Methods: 136 patients scheduled for elective hip and knee surgery were randomized to oral naloxegol or placebo given the morning of surgery, and on the first two postop- erative mornings. Residual urine volume was measured ultrasonographically within 30 min after voiding once in the morning and once in the afternoon for two postoperative days. Opioid-related Symptom Distress Scale (ORSDS), the need for indwelling urinary catheterization, and quality of recovery (QoR) score were secondary outcomes. Results: 67 were randomized to naloxegol and 64 to placebo. We did not identify a significant effect on urine residual volume, with an estimated ratio of geometric means of 0.9 (0.3, 2.6), p = 0.84. There were no significant differences in ORSDS or QoR. There were 19 (29%) patients assigned to naloxegol who needed indwelling urination catheterization versus 7 (11%) patients in the placebo group, p = 0.012. Conclusions: Our results do not support use of naloxegol for postoperative urinary retention after hip and knee surgery.
Keywords: anesthesia; urinary retention; naloxegol; residual bladder urine volume